Kyverna Therapeutics (KYTX) News
NASDAQ: KYTXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
4.26-0.11 (-2.52%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
KYTX news summary
We found 8 recent headlines mentioning Kyverna Therapeutics (KYTX): 0 in the past week and 5 in the past 30 days, most often from GlobeNewswire, Nasdaq. For price context, KYTX is down 2.52% at $4.26. The most recent story, "Kyverna Therapeutics, Inc. Announces Completion of BLA Submission for Miv-cel in Stiff Person Syndrome and Reports Third Quarter 2026 Financial Results", was published by Nasdaq on Nov 13, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Kyverna Therapeutics headlines
- Kyverna Therapeutics, Inc. Announces Completion of BLA Submission for Miv-cel in Stiff Person Syndrome and Reports Third Quarter 2026 Financial ResultsKyverna Therapeutics, Inc. has completed the submission of its rolling Biologics License Application to the U.S. Food and Drug Administration, seeking priority review of miv-cel in stiff person…NasdaqKYTX, WSO.B
- Kyverna Therapeutics Announces Completion of BLA Submission for Miv-cel in Stiff Person Syndrome and Reports Third Quarter 2026 Financial ResultsBLA submission for miv-cel in SPS completed with request for priority reviewGlobeNewswire
- Kyverna Therapeutics Announces Publication of Registrational Miv-cel Data in Patients with Stiff Person Syndrome in JAMA NeurologyPublication reinforces miv-cel's potential to deliver durable clinical benefit with a single dose, enabled by miv-cel's unique construct, and become the first approved therapy in SPS and first…GlobeNewswire
- Kyverna Therapeutics to Present at the Jefferies London Healthcare ConferenceEMERYVILLE, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical immunology company pioneering transformative therapies for people with…GlobeNewswire
- Oversold Conditions For Kyverna Therapeutics (KYTX)Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a…NasdaqKYTX, ET
- Kyverna Therapeutics Highlights Promising Updated Clinical Data with Miv-cel in Progressive Multiple Sclerosis at MS Toronto 2026Single-dose miv-cel continues to demonstrate promising clinical benefit in progressive multiple sclerosis, achieving robust CAR T-cell penetration in the central nervous system (CNS) and improving…GlobeNewswire
- Kyverna's Miv-cel Shows 49% Walking Improvement At One Year; Stock Down(RTTNews) - Kyverna Therapeutics, Inc. (KYTX) announced one-year results from its registrational Phase 2 KYSA-8 trial, demonstrating sustained clinical benefits of miv-cel in patients with stiff…NasdaqKYTX, SUN
- Kyverna Therapeutics Presents Full One-Year Registrational Data Set Demonstrating Sustained Clinical Benefit of Miv-cel in Stiff Person Syndrome at MS TorontoMiv-cel reversed disability and achieved durable efficacy across all primary and secondary endpoints through one year, with nearly all patients remaining off chronic immunotherapiesGlobeNewswire